---
title: "Summit Therapeutics Inc. (SMMT.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/SMMT.US.md"
symbol: "SMMT.US"
name: "Summit Therapeutics Inc."
industry: "Biotechnology"
---

# Summit Therapeutics Inc. (SMMT.US)

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Location | US Market |
| Website | [www.smmttx.com](https://www.smmttx.com) |

## Company Profile

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1...

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -13.28 | 469/604 | - | - | - |
| PB | 63.65 | 432/604 | 70.47 | 59.46 | 44.43 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-02-20T05:00:00.000Z

Total Analysts: **16**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 11 | 69% |
| Overweight | 1 | 6% |
| Hold | 3 | 19% |
| Underweight | 1 | 6% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 15.87 |
| Highest Target | 43.30 |
| Lowest Target | 12.33 |

## References

- [Company Overview](https://longbridge.com/en/quote/SMMT.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/SMMT.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/SMMT.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.